Here is his discussion in the cc.

07:00 in my laboratory State we have shown
07:02 that leronlimab effectively converts cd4
07:04 t-cells these are the targets of HIV
07:06 into ccr5 decisions that is they appear
07:09 as if they have come from the individual
07:11 with the ccr5 Delta 32 mutation


08:01 have been two individuals HIV positive
08:03 individuals who have been functionally
08:04 cured of HIV the so-called Berlin and
08:06 London patients there's also a third
08:09 patient called the essent patient who
08:11 has not yet been published all three of
08:13 these individuals received stem cell
08:14 transplants from ccr5 Delta 32 donors
08:17 so these are donors to lack the ccr5
08:19 molecule
08:20 thus it is currently believed in the HIV
08:22 field that ccr5 deficiency holds the key
08:24 to HIV cure as I mentioned earlier
08:27 Leronlimab administration effectively
08:29 converts cells in a patient's into the
08:30 ccr5 Delta 32 phenotype my laboratory
08:34 has established the only preclinical
08:35 non-human primate model of stem cell
08:37 transplantation we are currently testing
08:39 around the map as an ability to cure
08:41 these animals in stem cell
08:43 transplantation and based upon a results
08:46 in the science funding agencies are
08:48 eager to support both our preclinical
08:50 work and begin initiating human clinical
08:52 trials so specifically as far which is